Immunovaccine, Inc. - Product Pipeline Review - 2013
London (PRWEB) December 02, 2013 -- Immunovaccine, Inc. - Product Pipeline Review - 2013
Summary
Global Market Direct’s pharmaceuticals report, “Immunovaccine, Inc. - Product Pipeline Review - 2013” provides data on the Immunovaccine, Inc.’s research and development focus. The report includes information on current developmental pipeline, complete with latest updates, and features on discontinued and dormant projects.
This report is built using data and information sourced from Global Markets Direct’s proprietary databases, Immunovaccine, Inc.’s corporate website, SEC filings, investor presentations and featured press releases, both from Immunovaccine, Inc. and industry-specific third party sources, put together by Global Markets Direct’s team.
Scope
-Immunovaccine, Inc. - Brief Immunovaccine, Inc. overview including business description, key information and facts, and its locations and subsidiaries.
-Review of current pipeline of Immunovaccine, Inc. human therapeutic division.
-Overview of pipeline therapeutics across various therapy areas.
-Coverage of current pipeline molecules in various stages of drug development, including the combination treatment modalities, across the globe.
-Product profiles for late stage and clinical stage products of Immunovaccine, Inc. with complete description of the product’s developmental history, mechanism of action, therapeutic class, target and major milestones.
-Recent updates of the Immunovaccine, Inc.’s pipeline in the last quarter.
-Key discontinued and dormant projects.
-Latest news and deals relating to the products.
Reasons to buy
-Evaluate Immunovaccine, Inc.’s strategic position with total access to detailed information on its product pipeline.
-Assess the growth potential of Immunovaccine, Inc. in its therapy areas of focus.
-Identify new drug targets and therapeutic classes in the Immunovaccine, Inc.’s R&D portfolio and develop key strategic initiatives to reinforce pipeline in those areas.
-Exploit in-licensing opportunities by identifying windows of opportunity to fill portfolio gaps.
-Exploit collaboration and partnership opportunities with Immunovaccine, Inc..
-Avoid Intellectual Property Rights related issues.
-Explore the dormant and discontinued projects of Immunovaccine, Inc. and identify potential opportunities in those areas.
Table of Contents
Table of Contents 2
List of Tables 4
List of Figures 4
Immunovaccine, Inc. Snapshot 5
Immunovaccine, Inc. Overview 5
Key Information 5
Key Facts 5
Immunovaccine, Inc. - Research and Development Overview 6
Key Therapeutic Areas 6
Immunovaccine, Inc. - Pipeline Review 9
Pipeline Products by Stage of Development 9
Pipeline Products - Monotherapy 10
Immunovaccine, Inc. - Pipeline Products Glance 11
Immunovaccine, Inc. Clinical Stage Pipeline Products 11
Phase II Products/Combination Treatment Modalities 11
Phase I Products/Combination Treatment Modalities 12
Immunovaccine, Inc. - Early Stage Pipeline Products 13
Preclinical Products/Combination Treatment Modalities 13
Discovery Products/Combination Treatment Modalities 14
Immunovaccine, Inc. - Drug Profiles 15
Anthrax Vaccine 15
Product Description 15
Mechanism of Action 15
R&D Progress 15
Cocaine Addiction Vaccine 16
Product Description 16
Mechanism of Action 16
R&D Progress 16
Dengue Fever Vaccine 17
Product Description 17
Mechanism of Action 17
R&D Progress 17
DPX-0907 18
Product Description 18
Mechanism of Action 18
R&D Progress 18
DPX-Survivac 19
Product Description 19
Mechanism of Action 19
R&D Progress 19
Hepatitis B Vaccine 20
Product Description 20
Mechanism of Action 20
R&D Progress 20
Herpes Simplex Virus 2 Vaccine 21
Product Description 21
Mechanism of Action 21
R&D Progress 21
HIV Vaccine 22
Product Description 22
Mechanism of Action 22
R&D Progress 22
Malaria Vaccine 23
Product Description 23
Mechanism of Action 23
R&D Progress 23
Pandemic Influenza Vaccine 24
Product Description 24
Mechanism of Action 24
R&D Progress 24
Respiratory Syncytial Virus Vaccine 25
Product Description 25
Mechanism of Action 25
R&D Progress 25
Tuberculosis Vaccine 26
Product Description 26
Mechanism of Action 26
R&D Progress 26
Vaccine For Multifiloviruses 27
Product Description 27
Mechanism of Action 27
R&D Progress 27
Immunovaccine, Inc. - Pipeline Analysis 28
Immunovaccine, Inc. - Pipeline Products by Therapeutic Class 28
Immunovaccine, Inc. - Pipeline Products By Target 30
Immunovaccine, Inc. - Pipeline Products by Route of Administration 31
Immunovaccine, Inc. - Recent Pipeline Updates 32
Immunovaccine, Inc. - Dormant Projects 37
Immunovaccine, Inc. - Discontinued Pipeline Products 38
Discontinued Pipeline Product Profiles 38
DPX-Pseudomonas 38
Immunovaccine, Inc. - Locations And Subsidiaries 39
Head Office 39
Appendix 40
Methodology 40
Coverage 40
Secondary Research 40
Primary Research 40
Expert Panel Validation 40
Contact Us 41
Disclaimer 41
List of Tables
Immunovaccine, Inc., Key Information 5
Immunovaccine, Inc., Key Facts 5
Immunovaccine, Inc. - Pipeline by Indication, 2013 8
Immunovaccine, Inc. - Pipeline by Stage of Development, 2013 9
Immunovaccine, Inc. - Monotherapy Products in Pipeline, 2013 10
Immunovaccine, Inc. - Phase II, 2013 11
Immunovaccine, Inc. - Phase I, 2013 12
Immunovaccine, Inc. - Preclinical, 2013 13
Immunovaccine, Inc. - Discovery, 2013 14
Immunovaccine, Inc. - Pipeline By Therapeutic Class, 2013 29
Immunovaccine, Inc. - Pipeline By Target, 2013 30
Immunovaccine, Inc. - Pipeline By Route of Administration, 2013 31
Immunovaccine, Inc. - Recent Pipeline Updates, 2013 32
Immunovaccine, Inc. - Dormant Developmental Projects,2013 37
Immunovaccine, Inc. - Discontinued Pipeline Products, 2013 38
List of Figures
Immunovaccine, Inc. - Pipeline by Indication, 2013 7
Immunovaccine, Inc. - Pipeline by Stage of Development, 2013 9
Immunovaccine, Inc. - Monotherapy Products in Pipeline, 2013 10
Immunovaccine, Inc. - Pipeline By Therapeutic Class, 2013 28
Immunovaccine, Inc. - Pipeline By Route of Administration, 2013 31
Companies Mentioned
Read the full report:
Immunovaccine, Inc. - Product Pipeline Review - 2013
For more information:
Sarah Smith
Research Advisor at Reportbuyer.com
Email: [email protected]
Tel: +44 208 816 85 48
Website: http://www.reportbuyer.com/
Sarah Smith, Research Advisor at Reportbuyer.com, +44 208 816 85 48, [email protected]
Share this article